Foundayo Is Here: What Your Doctor Needs to Know Before Prescribing It

On April 1, 2026, the FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 medication made by Eli Lilly. It's the second oral GLP-1 approved for weight management — following oral Wegovy's approval in December 2025 — but it works differently in ways that matter for patients.

If you're considering asking your doctor about Foundayo, or if you're already on a GLP-1 and wondering whether to switch, this guide covers what you need to know before your appointment.

What Is Foundayo and How Is It Different?

Foundayo is a small-molecule GLP-1 receptor agonist. Unlike injectable semaglutide (Wegovy) or tirzepatide (Zepbound), you take it as a daily pill. But unlike oral Wegovy — which must be taken first thing in the morning on an empty stomach with no more than four ounces of water, then waiting 30 minutes before eating — Foundayo has no food or water restrictions.

That's a meaningful clinical difference. Take it at breakfast, take it at dinner, take it with coffee. For patients who struggled with oral Wegovy's strict fasting protocol, Foundayo removes that barrier entirely.

The ATTAIN-1 Trial Numbers

Foundayo's approval was based on the ATTAIN clinical trial program. Here are the key numbers your doctor should know:

Metric	Foundayo (36mg)	Placebo
Average weight loss (on-treatment)	12.4% (~27 lbs)	0.9% (~2 lbs)
Average weight loss (all participants)	11.1% (~25 lbs)	2.1% (~5 lbs)
Treatment duration	72 weeks
Dosing	Once daily, oral, no food/water restrictions

For context, injectable Wegovy (2.4mg) produces roughly 15% weight loss at 68 weeks, and Zepbound at its highest doses produces roughly 20%. Foundayo's numbers are lower — but it's a pill you take any time of day, which may significantly improve real-world adherence.

Who Is a Good Candidate for Foundayo?

Foundayo is FDA-approved for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, used alongside a reduced-calorie diet and increased physical activity.

It may be especially appropriate if you:

• Have a strong needle aversion — Needle phobia is the #1 reason patients avoid injectable GLP-1s
• Travel frequently — No cold chain storage required (unlike injectable medications)
• Struggled with oral Wegovy's dosing restrictions — No morning fasting requirement
• Prioritize convenience over maximum efficacy — A pill you can take any time may produce better results than an injection you skip
• Are Medicare-eligible — Foundayo is covered under the Medicare GLP-1 Bridge program starting July 1, 2026 at $50/month

Who Should Not Take Foundayo?

Foundayo carries the same class-level precautions as other GLP-1 medications. Your doctor should screen for:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis
• Pregnancy or plans to become pregnant — Foundayo's label explicitly warns it may harm a developing fetus and can reduce the effectiveness of birth control pills
• Current use of another GLP-1 receptor agonist (don't combine them)

Important: Foundayo can make birth control pills less effective. If you're on oral contraception, discuss backup methods with your doctor before starting.

Common Side Effects

The side effect profile is similar to injectable GLP-1s, with gastrointestinal symptoms being most common:

• Nausea (most common, especially during titration)
• Constipation and diarrhea
• Vomiting and dyspepsia
• Abdominal pain and bloating
• Headache and fatigue
• Hair loss (reported in ≥5% of participants)

Most GI side effects improve as your body adjusts, typically within the first 4–8 weeks. Your doctor should start you on the lowest dose and titrate up gradually.

Foundayo vs. Oral Wegovy: Which One?

This is the question many patients will bring to their appointment. Here's how they compare:

Feature	Foundayo	Oral Wegovy
Drug	Orforglipron (Lilly)	Semaglutide (Novo Nordisk)
Dosing	Once daily, any time	Once daily, morning only
Food restrictions	None	Empty stomach, 30-min wait
Water restrictions	None	≤ 4 oz only
Weight loss	~12.4% at 72 weeks	~15% (OASIS-1 data)
Medicare Bridge	Yes ($50/mo)	Yes ($50/mo)
Molecule type	Small molecule (non-peptide)	Peptide (requires SNAC absorption)

The bottom line: Oral Wegovy may produce slightly more weight loss, but Foundayo is significantly more convenient to take. If you know you'll struggle with fasting requirements and morning-only dosing, Foundayo's ease of use could translate to better real-world results through better adherence.

Questions to Bring to Your Appointment

If you're considering Foundayo, bring these questions to your doctor:

1. "Given my BMI and health history, am I a candidate for Foundayo specifically?"
2. "I'm currently on [medication] — are there any interactions with orforglipron?"
3. "How does the titration schedule work, and what should I expect in the first month?"
4. "Am I eligible for the Medicare GLP-1 Bridge program, or should I look at cash-pay options?"
5. "If I don't respond well to Foundayo after 3 months, what's the next step?"

How to Access Foundayo

Foundayo is available through LillyDirect (Lilly's direct-to-patient platform), most retail pharmacies, and licensed telehealth providers. For Medicare patients, the GLP-1 Bridge program covers Foundayo at $50/month starting July 1, 2026.

For patients without insurance or Medicare, cash-pay pricing will vary. Telehealth platforms that offer brand-name prescribing may be the fastest route to access.

If brand-name pricing is a barrier, compounded semaglutide remains a lower-cost alternative starting under $150/month through licensed telehealth providers — though it's a different medication with different trade-offs.

The Bigger Picture

Foundayo's approval marks a genuine turning point. For the first time, patients have an oral GLP-1 option that doesn't require fasting, water restrictions, or injections. Combined with the Medicare Bridge program launching in July, access to effective weight loss medication is broader than it's ever been.

But "new" doesn't automatically mean "better for you." Your doctor's job is to evaluate whether Foundayo fits your specific clinical picture — and your job is to come prepared with the right questions. Bring this guide to your appointment.